Evidence for a Potent Angiotensin I Degrading Enzyme Different from Angiotensin I Converting Enzyme in Rat Vascular Tissues
There are indications for the existence of an intrinsic renin angiotensin system in vascular walls, which is assumed to participate in blood pressure regulation and in pathogenesis of arterial hypertension. It was evaluated if and to what extent the decapeptide angiotensin (A) I, one of the natural substrates of A I converting enzyme (ACE), is degraded by other peptidases than ACE in rat vascular tissues. A I and A II degradation was studied in arterial and venous vascular wall extracts. The activities ranged between 0.068 ± 0.025 U and 0.044 ± 0.025 U. The enzymes involved were biochemically characterized by determination of isoelectric points (pI), pH optima, molecular weights and by investigation of their inhibition behavior in vitro. One potent A I degrading enzyme (AIDE) was identified with pI between 3.6 and 3.9, and pH optimum at 7.75. In vitro studies revealed that AIDE activity was not blocked by the specific ACE inhibitors MK 421 or MK 422 (both 11 nMol/ml). The molecular weight of AIDE ranged between 440,000 and 457,000. The results indicate that AIDE is not identical to ACE (pI 4.2–5.0; pH optimum 8.3). AIDE was also observed in aortic smooth muscle cells cultured in vitro. AIDE decreased following bilateral nephrectomy or administration of aldosterone combined with sodium chloride loading, whereas it was elevated in spontaneously hypertensive rats (Okamoto strain). Since AIDE metabolizes A I, one of the substrates of ACE, it may indirectly affect A II formation and bradykinin inactivation as well.
KeywordsGlycerol Ethyl Albumin Sodium Chloride Angiotensin
Unable to display preview. Download preview PDF.
- 1.H. Dahlheim, I. C. M. Jacob, J. Pschorr, and J. Rosenthal, The renin angiotensin system in the extrarenal vascular walls: An approach to studies in humans, in: “Hormones in Normal and Abnormal Human Tissues,” Vol. 3, K. Fotherby and S. B. Pal, eds., Walter de Gruyter & Co., Berlin, New York (1983).Google Scholar
- 2.Z. P. Horowitz, Pharmacology and mechanism of action of inhibitors of the renin angiotensin system, in: “Drug Development and Evaluation, Vol 4: Pharmacology and Use of Angiotensin I Converting Enzyme Inhibitors,” F. Gross and R. K. Liedtke, eds., Fischer-Verlag, Stuttgart, New York (1980).Google Scholar
- 4.W. Burghardt, H. Schweisfurth,, and H. Dahlheim, Juxtaglomerular angiotensin II formation, Kidney Int., 22 (Suppl. 12): S49–S54 (1982).Google Scholar
- 9.H. Dahlheim and E. Schmidmeier, Determination and characterization of angiotensinase activity of microdissected juxtaglomerular apparatuses (JGA) of the rat kidney, Abstract, Vth International Congress of Nephrology, Mexico, 119 (1972).Google Scholar
- 10.W. A. Rightsel, T. Okamura, T. Inagami, J. A. Pitcock,, Y. Takii, B. Brooks, P. Brown, and E. E. Muirhead, Juxtaglomerular cells grown as monolayer cell culture contain renin, angiotensin I-converting enzyme, and angiotensins I and II/III, Circ. Res., 50 (6): 822–829 (1982).Google Scholar